Anti-JAK2/ JAK-2/ JTK10 monoclonal antibody
Anti-JAK2/ JAK-2/ JTK10 antibody for FACS & in-vivo assay
Go to JAK-2/JAK2 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-T08391-Ab-1/ GM-Tg-hg-T08391-Ab-2 | Anti-Human JAK-2/JAK2 monoclonal antibody | Human |
GM-Tg-rg-T08391-Ab-1/ GM-Tg-rg-T08391-Ab-2 | Anti-Rat JAK-2/JAK2 monoclonal antibody | Rat |
GM-Tg-mg-T08391-Ab-1/ GM-Tg-mg-T08391-Ab-2 | Anti-Mouse JAK-2/JAK2 monoclonal antibody | Mouse |
GM-Tg-cynog-T08391-Ab-1/ GM-Tg-cynog-T08391-Ab-2 | Anti-Cynomolgus/ Rhesus macaque JAK-2/JAK2 monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-T08391-Ab-1/ GM-Tg-felg-T08391-Ab-2 | Anti-Feline JAK-2/JAK2 monoclonal antibody | Feline |
GM-Tg-cang-T08391-Ab-1/ GM-Tg-cang-T08391-Ab-2 | Anti-Canine JAK-2/JAK2 monoclonal antibody | Canine |
GM-Tg-bovg-T08391-Ab-1/ GM-Tg-bovg-T08391-Ab-2 | Anti-Bovine JAK-2/JAK2 monoclonal antibody | Bovine |
GM-Tg-equg-T08391-Ab-1/ GM-Tg-equg-T08391-Ab-2 | Anti-Equine JAK-2/JAK2 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-T08391-Ab-1/ GM-Tg-hg-T08391-Ab-2; GM-Tg-rg-T08391-Ab-1/ GM-Tg-rg-T08391-Ab-2; GM-Tg-mg-T08391-Ab-1/ GM-Tg-mg-T08391-Ab-2; GM-Tg-cynog-T08391-Ab-1/ GM-Tg-cynog-T08391-Ab-2; GM-Tg-felg-T08391-Ab-1/ GM-Tg-felg-T08391-Ab-2; GM-Tg-cang-T08391-Ab-1/ GM-Tg-cang-T08391-Ab-2; GM-Tg-bovg-T08391-Ab-1/ GM-Tg-bovg-T08391-Ab-2; GM-Tg-equg-T08391-Ab-1/ GM-Tg-equg-T08391-Ab-2 |
Products Name | Anti-JAK-2/JAK2 monoclonal antibody |
Format | mab |
Target Name | JAK-2 |
Protein Sub-location | Transmembrane Protein |
Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-JAK-2 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | Products Developing | Multi-species JAK2/ JAK-2/ JTK10 VLP (virus-like particle) (Products Developing) |
ORF Viral Vector | pGMLPm003630 | mouse Jak2 Lentivirus plasmid |
ORF Viral Vector | vGMLPm003630 | mouse Jak2 Lentivirus particle |
Target information
Target ID | GM-T08391 |
Target Name | JAK-2 |
Gene ID | 3717,16452,24514,694184,484185,101088959,525246,100051487 |
Gene Symbol and Synonyms | Fd17,JAK2,JTK10 |
Uniprot Accession | O60674,Q62689 |
Uniprot Entry Name | JAK2_HUMAN,JAK2_RAT |
Protein Sub-location | Transmembrane Protein |
Category | Therapeutics Target |
Disease | Cancer |
Gene Ensembl | ENSG00000096968 |
Target Classification | Kinase, Tumor-associated antigen (TAA) |
The target: JAK-2, gene name: JAK2, also named as JTK10, THCYT3. This gene encodes a non-receptor tyrosine kinase that plays a central role in cytokine and growth factor signalling. The primary isoform of this protein has an N-terminal FERM domain that is required for erythropoietin receptor association, an SH2 domain that binds STAT transcription factors, a pseudokinase domain and a C-terminal tyrosine kinase domain. Cytokine binding induces autophosphorylation and activation of this kinase. This kinase then recruits and phosphorylates signal transducer and activator of transcription (STAT) proteins. Growth factors like TGF-beta 1 also induce phosphorylation and activation of this kinase and translocation of downstream STAT proteins to the nucleus where they influence gene transcription. Mutations in this gene are associated with numerous inflammatory diseases and malignancies. This gene is a downstream target of the pleiotropic cytokine IL6 that is produced by B cells, T cells, dendritic cells and macrophages to produce an immune response or inflammation. Disregulation of the IL6/JAK2/STAT3 signalling pathways produces increased cellular proliferation and myeloproliferative neoplasms of hematopoietic stem cells. A nonsynonymous mutation in the pseudokinase domain of this gene disrupts the domains inhibitory effect and results in constitutive tyrosine phosphorylation activity and hypersensitivity to cytokine signalling. This gene and the IL6/JAK2/STAT3 signalling pathway is a therapeutic target for the treatment of excessive inflammatory responses to viral infections. Alternative splicing results in multiple transcript variants encoding distinct isoforms. [provided by RefSeq, Jul 2020].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.